Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
Kyverna Therapeutics to Participate in Upcoming September Investor Conferences
EMERYVILLE, Calif., Aug. 21, 2024 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today that the company's executives will participate in the following investor events:
加利福尼亞伊默裏維爾，2024年8月21日/美通社——Kyverna Therapeutics，Inc.(Kyverna)，一家以患者爲中心的臨床階段生物製藥公司，專注於開發細胞治療技術，治療患有自身免疫性疾病的患者，今天宣佈公司高管將參加以下投資者活動：
Investor Conference Details:
投資者會議詳情：
- Morgan Stanley Global Healthcare Conference in New York, NY on September 4, 2024
Format: Fireside Chat with Mike Ulz at 11:30 am EDT and host investor meetings - Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024
Format: Fireside Chat with Derek Archila at 2:15 pm EDT and host investor meetings - Cantor Global Healthcare Conference in New York, NY on September 17, 2024
Format: Fireside Chat with Eric Schmidt at 10:20 am EDT and host investor meetings
- 摩根士丹利全球醫療保健大會，地點：紐約，日期：2024年9月4日
形式：與Mike Ulz的爐邊談話，早上11點30分(東部時間)，並主持投資者會議 - 富國銀行保健大會，地點：波士頓，日期：2024年9月5日
形式：與Derek Archila的爐邊談話，下午2點15分(東部時間)，並主持投資者會議 - 康泰爾全球醫療保健大會，地點：紐約，日期：2024年9月17日
形式：與Eric Schmidt的爐邊談話，上午10點20分(東部時間)，並主持投資者會議
Investors interested in scheduling a meeting with management during one of the investor conferences listed above should contact their Morgan Stanley, Wells Fargo, or Cantor sales representative.
有意在上述投資者大會期間與管理層安排會議的投資者應聯繫他們的摩根士丹利、富爾頓或康托爾銷售代表。
About Kyverna Therapeutics
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.
關於Kyverna Therapeutics
Kyverna Therapeutics，Inc.（納斯達克：KYTX）是一家以患者爲中心的，處於臨床階段的生物製藥公司，專注於爲患有自身免疫性疾病的患者開發細胞治療方案。我們的主要CAR T細胞治療候選藥KYV-101正在通過臨床開發，在兩個自身免疫性疾病的廣泛領域中進行贊助臨床試驗：風溼病學和神經學，其中包括難治性僵硬人綜合症、多發性硬化症和重症肌無力的二期試驗，系統性硬化症的一期/二期試驗，在美國和德國進行的兩個正在進行的多中心、開放標籤的一期/二期試驗，以治療狼瘡性腎炎的一個多中心隨機III期試驗。
Our lead CAR T-cell therapy candidate, KYV-101, is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center, open-label Phase 1/2 trials in the United States and Germany for patients with lupus nephritis.
我們的CAR T細胞療法候選者KYV-101正在臨床發展中，涵蓋了風溼病學和神經學兩個廣泛領域的贊助臨床試驗，其中包括僵硬人綜合徵、多發性硬化症和重症肌無力的2期試驗，全身性硬化症的1/2期試驗，以及美國和德國針對狼瘡性腎炎患者進行的兩項正在進行的多中心開放性1/2期試驗。
Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
Kyverna的開發項目包括自體和異體下一代CAR T細胞治療方案，其特性適合於B細胞驅動的自身免疫性疾病。
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: Kyverna's expected participation in upcoming investor conferences; Kyverna's ongoing clinical trials; Kyverna's pipeline and the potential for Kyverna's CAR T-cell therapies to be well suited for use in B cell-driven autoimmune diseases. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
前瞻性聲明
本新聞稿中的關於未來預期、計劃和前景的陳述，以及任何其他關於非歷史事實的事項的陳述，可能構成「前瞻性陳述」。這些詞彙，包括但不限於「預計」，「相信」，「繼續」，「可能」，「估計」，「期望」，「打算」，「可能」，「計劃」，「潛力」，「預測」，「項目」，「應該」，「目標」，「將」，「會」和類似表述的目的是用於識別前瞻性陳述，雖然並非所有前瞻性陳述都包含這些或類似的識別詞語。本新聞稿中的前瞻性陳述包括但不限於以下內容：Kyverna有望參加即將舉行的投資者大會；Kyverna正在進行的臨床試驗；Kyverna的候選CAR T細胞療法對B細胞驅動的自身免疫疾病可能非常適用。實際結果可能因各種重要因素而與此類前瞻性陳述有所不同，包括市場狀況的不確定性以及Kyverna在其最近的年度報告的「風險因素」部分和在其已或將隨後向美國證券交易委員會提交的季度報告的「風險因素」部分中討論的其他因素。本新聞稿中包含的任何前瞻性陳述都是基於Kyverna管理團隊的當前預期，僅於此日期發佈，並且Kyverna明確表示不承擔任何更新任何前瞻性陳述的義務，無論是因爲新信息、未來事件還是其他原因導致的。
For more information, please visit .
Investor Contact:
George Thampy
Kyverna Therapeutics
[email protected]
有關更多信息，請訪問 .
投資者聯繫人：
George Thampy
Kyverna Therapeutics
[email protected]
Kyverna Media Contact:
Consort Partners for Kyverna
[email protected]
Kyverna媒體聯繫人：
Kyverna與Consort Partners合作
[email protected]
SOURCE Kyverna Therapeutics
Kyverna Therapeutics
譯文內容由第三人軟體翻譯。